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ABSTRACT
Objective: The aim of this study was to monitor the side effects in patients who received aminoglycoside antibiotics at the inpatient service of 
Fatmawati Hospital from March to May 2017.
Methods: This was an observational study based on data collected through patient interview, prescribing information, and medical records. Data 
were collected on all inpatients treated with aminoglycosides during the study period (total sampling method). The Naranjo algorithm was used to 
assess the causality of the observed effects.
Results: The data from 33 patients were evaluated, among whom 14 (42.4%) developed nephrotoxicity and 5 (15.2%) had ototoxicity. Based on the 
Naranjo algorithm analysis, the five cases of ototoxicity were categorized as probable drug side effects. No correlation was found between any of the 
side effects and either age (p=0.726) or sex (p=0.620).
Conclusion: In this evaluation of the side effects attributable to aminoglycoside antibiotics in hospitalized patients, nephrotoxicity was the most 
common, followed by ototoxicity. The latter was deemed probable drug-related side effects based on the Naranjo algorithm. Of the other side effects, 
twice as many were considered probable as those thought to be possible drug side effects. Neither age nor sex was significantly related to the adverse 
effects secondary to gentamicin or amikacin.
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INTRODUCTION
Aminoglycoside antibiotics are often used for infectious diseases but 
may cause serious side effects [1]. Large to scale studies have shown 
that, among 10,000 adult patients given tobramycin, amikacin, or 
gentamicin, the incidence of nephrotoxicity ranges from 9.4% to 
14%, cochlear toxicity from 6.1% to 13.9%, and vestibular toxicity 
from 2.8% to 3.5%. In pediatric patients including neonates, 1.6% 
reportedly had decreased renal function and 2%–2.3% had muscle 
toxicity [2-5].
Pharmaceutical services guidelines for antibiotic therapy states 
that the side effects of aminoglycoside antibiotics, particularly 
nephrotoxicity, necessitate to monitor aminoglycoside side effects 
of blood drug levels, particularly in patients with underlying renal 
impairment [6]. Monitoring of aminoglycoside blood drug levels is 
important because these agents have a narrow therapeutic index, 
including the commonly used agents gentamicin, amikacin, and 
tobramycin [7,8].
Given the serious side effects that can be caused by aminoglycosides, 
practitioners are encouraged to monitor drug side effects including 
postmarketing monitoring of drugs already approved for use. The 
Naranjo algorithm was developed to help determine whether a 
particular adverse effect is likely to have been caused by a drug [9]. 
This study was undertaken at Fatmawati Hospital, a general hospital 
and referral center in Jakarta, Indonesia. Monitoring of the side 
effects of aminoglycoside antibiotics with a narrow therapeutic index 
had not been widely practiced before this study. Since gentamicin 
and amikacin were the only two aminoglycosides available in our 
hospital, this study focuses on those two agents. The purpose of this 
study was to evaluate the side effects of aminoglycosides prescribed 
in the hospital.
METHODS
This was an observational prospective cohort study based on data 
collected from patient interview, prescription information, medical 
records, and nurses’ notes at Fatmawati Hospital from March to May 
2017. Records of inpatients aged 1 month and older were included 
if the patient met the following criteria: (1) Received gentamicin or 
amikacin for ≥7 days, either as a sole medication or in combination 
with other antibiotics, (2) had normal serum creatinine levels 
before aminoglycoside administration (i.e., 0.6–1.5 mg/dL in adults, 
0.0–0.9 mg/dL in children), and (3) the patient or a family member 
was available for interview. The exclusion criteria were the use of other 
drugs that may increase the side effects of gentamicin or amikacin and 
incomplete or illegible medical record data.
The data were analyzed with the Naranjo algorithm to assess the 
causality of adverse events. We assessed the following variables: Sex, 
age, type of aminoglycoside, dosage regimen, duration of administration, 
and combinations with other antibiotics. The Chi-square test was used 
to analyze a possible correlation between age or sex and the incidence 
of side effects. IBM SPSS Statistics for Windows version 24.0 by IBM 
Corp. (New York) was used to analyze all the data.
RESULTS
During the study period, 42 patients were treated with an 
aminoglycoside. We excluded two neonates whose family could not be 
interviewed and six patients treated with gentamicin or amikacin for 
<7 days. One another patient died during treatment, leaving 33 patients 
included in the study. Of these 33, 19 were male and 17 were adults 
aged 18–60 years. Amikacin was given to 18 patients with a 1 g once 
daily (30.30% of total patients) dosing regimen for <2 weeks (15 of 
whom took it for <2 weeks). The most common antibiotic combination 
was gentamicin with ceftriaxone (36.36% of total patients).
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Side effects of gentamicin or amikacin included nephrotoxic, ototoxic, 
and others. Nephrotoxicity occurred in 14 patients and ototoxicity in 5 
(Table 1). All five cases of ototoxicity were categorized by the Naranjo 
algorithm as probable drug-related side effects (Table 2). Among the 
other side effects occurring in 15 patients, 10 incidents were considered 
probable and 5 possible drug side effects.
DISCUSSION
Nephrotoxic side effects
The serum creatinine values were elevated above normal in two patients 
on amikacin, but in none of the patients treated with gentamicin. Elevated 
serum creatinine values indicate a decrease in kidney function [6]. 
Therefore, of the 33 study patients receiving an aminoglycoside, 
2 (6.06%) adults possibly had a slight decrease in kidney function.
However, based on the creatinine clearance (Cockcroft-Gault equation), 
14 patients (42.4%) had evidence of nephrotoxicity. Among patients 
receiving amikacin, a 27% decrease in estimated glomerular filtration 
rate (eGFR) occurred in five patients including two adults and three 
children. The decrease in eGFR was considered mild to moderate in 
two adults, moderate to severe in one adult, and severe in one adult. 
There was no decrease in eGFR in children samples. Among patients on 
Table 1: Side effects of gentamicin or amikacin
Category Adults (n=17) (>18 years) Children (n=16) (≤18 years) Total n (%)
Serum creatinine (mg/dL) Normal (0.6–1.5 mg/dL) Normal (0.0–0.9 mg/dL)
Amikacin
Below normal 4 0 4 (12.12)
Normal 4 8 12 (36.36)
Above normal 2 0 6.06
Gentamicin
Below normal 2 0 2 (6.06)
Normal 10 3 13 (39.40)
Above normal 0 0 0 (0.00)
Creatinine clearance (mL/min) Normal (>90 mL/min)
Amikacin
>90 4 −5 9 (27.27)
60–89 2 3 5 (15.15)
45–59 2 0 2 (6.06)
30–44 1 0 1 (3.03)
15–29 1 0 1 (3.03)
<15 0 0 0 (0.00)
Gentamicin
>90 6 4 10 (30.30)
60–89 4 0 0 (12.12)
45–59 0 0 0 (0.00)
30–44 1 0 1 (3.03)
15–29 0 0 0 (0.00)
<15 0 0 0 (0.00)
Table 2: Side effects ototoxicity of gentamicin or amikacin
Side effects ototoxicity Age category Total n (%)
Toddlers Children Adolescents Adults Elderly
Amikacin
Tinnitus 0 0 1 1 0 2 (6.06)
Hearing disorders 0 0 0 0 0 0 (0.00)
Vertigo 0 0 0 0 0 0 (0.00)
Ataxia 0 0 0 0 0 0 (0.00)
Nystagmus 0 0 0 0 0 0 (0.00)
Gentamicin
Tinnitus 0 0 0 1 0 1 (3.03)
Hearing disorders 0 0 0 0 0 0 (0.00)
Vertigo 0 0 1 1 0 2 (6.06)
Ataxia 0 0 0 0 0 0 (0.00)
Nystagmus 0 0 0 0 0 0 (0.00)
Amikacin
Drowsiness 0 1 0 1 0 2 (6.06)
Nausea and Vomiting 2 1 0 0 0 3 (9.09)
Headache 0 0 0 0 0 0 (0.00)
Rash 1 0 0 0 0 1 (3.03)
Tremor 0 0 0 0 0 0 (0.00)
Paresthesia 0 0 0 0 0 0 (0.00)
Gentamicin
Drowsiness 1 0 1 1 0 3 (9.09)
Nausea and vomiting 0 0 1 1 0 2 (6.06)
Headache 0 0 1 1 0 1 (3.03)
Rash 0 0 0 0 0 0 (0.00)
Decreased appetite 0 0 0 0 1 1 (3.03)
Tremor 1 0 0 0 0 1 (3.03)
Paresthesia 0 0 0 1 0 1 (3.03)
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gentamicin, there was a 15% decrease in eGFR among four adults, one 
of whom had a moderate to severe decrease.
The incidence of nephrotoxicity in this study was higher than that found 
by Overview et al. who reported a 10% incidence of aminoglycoside-
induced nephrotoxicity [10]. According to the Drug Information 
Handbook, the incidence of nephrotoxicity ranged from 1% to 10% [8]. 
By contrast, Pogue et al. reported an incidence of aminoglycoside 
to related nephrotoxicity of 58% among patients in an intensive 
care unit [11]. Mortality was significantly higher among those with 
nephrotoxicity than among those without acute renal injury (45% vs. 
29%). The wide variation in the results may be due to the differences in 
the patient populations in each study.
Ototoxic side effects
Ototoxicity occurred in 5 (15.2%) of our patients, three of whom were 
taking gentamicin. Tinnitus was reported in one adult and vertigo in 
one adolescent and one adult. Tinnitus occurred with amikacin in one 
adolescent and one adult.
These findings are in accord with the review by Xie et al. They 
summarized several studies of aminoglycoside treatment of acute 
infections lasting 5–7 days, indicating that the drugs caused hearing 
loss in about 20% and loss of balance in 15% [12]. The drug information 
handbook stated that the incidence of ototoxic events is 1–10% [13]. 
Ototoxic side effects might also be more likely to occur in the elderly or 
patients who previously had previously suffered hearing damage [14]. 
In our study, all the five occurrences of ototoxicity were deemed to 
be probable side effects of the antibiotics according to the Naranjo 
algorithm.
Other side effects
Other side effects potentially attributable to aminoglycosides were 
reported in 15 of the 33 patients (45.5%). These occurred in nine 
patients treated with gentamicin, including drowsiness in three (one 
infant, one adolescent, and one adult), nausea and vomiting in two 
(one adolescent and one adult), headache in one adult, anorexia in one 
adult, tremors in one infant, and paresthesia in one adult. Among those 
taking amikacin, six patients experienced other side effects including 
drowsiness in two (one child and one adult), nausea and vomiting in 
three (two infants and one child), and rash in one infant.
The incidence of other adverse events in this study was greater than the 
<1% noted in the drug information handbook [13]. Hypersensitivity 
reactions are rare except with topical administration with which 
the incidence is 10% [14]. The difference between the incidence of 
other side effects in our study and what is reported in the literature 
may simply be a statistical anomaly due to our small sample size 
of 33 patients. Among the 15 other effects we observed, 10 were 
considered probable and 5 possible drug-related effects according to 
the Naranjo scale.
Based on this research, the result of the Chi-square test between age 
and side effect stated that 90% of the data had <5 expectation value; 
thus, likelihood ratio analysis test with significance value (two-sided) 
was used. 0.726 or >0.05 value was obtained. The results of the Chi-
square analysis showed no association between age and side effects 
attributable to gentamicin or amikacin. Selimoglu stated that among 
8333 pediatric patients, 6.0% had nephrotoxicity secondary to an 
aminoglycoside, although there was no assessment of a relationship 
between age and the incidence of side effects [15].
The results of the Chi-square test between sex and side effects showed 
that > 50% of the data had expectation value <5, so Fisher’s exact test 
was used. The analysis indicated no significant relationship between 
sex and side effects caused by gentamicin or amikacin. Sweileh found 
a significantly higher incidence of nephrotoxicity among women than 
men taking amikacin; however, there was no such sex difference for 
gentamicin-induced nephrotoxicity [16].
CONCLUSION
In this evaluation of the side effects attributable to aminoglycoside 
antibiotics in hospitalized patients, nephrotoxicity was the most 
common, followed by ototoxicity. The latter was deemed probable 
drug-related side effects based on the Naranjo algorithm. Of the other 
side effects, twice as many were considered probable as those thought 
to be possible drug side effects. Neither age nor sex was significantly 
related to the adverse effects secondary to gentamicin or amikacin.
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